Constellation Pharmaceuticals, Inc. today announced that it has appointed Edward E. Harlow, Jr., Ph.D. as the company`s Chief Scientific Officer. This appointment reflects the Company`s strong scientific heritage and its progress in building the leading biopharmaceutical effort focused on discovering and developingnew drugs targeting epigenetic regulation of the human genome. Dr. Harlow will direct Constellation`s research and drug discovery efforts,initially focused on new treatments for cancer.
Dr. Harlow, a distinguished molecular biologist, is an internationally recognized leader in cancer biology who is best known for his discoveries regarding the control of cell division and critical changes that allow cancer to develop. He most recently served as Professor and Chair of the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and
Associate Director of the Dana-Farber/Harvard Cancer Center. Previously he served as Scientific Director for the Massachusetts General Hospital Cancer Center and was Associate Director for Science Policy at the National Cancer Institute, where he helped direct U.S. cancer research planning. Dr. Harlow has received numerous scientific honors, including election to the National Academy of Sciences and the Institute of Medicine, appointment as Fellow of the American Academy of Arts and Sciences, and receipt of the American Cancer Society`s highest award, the Medal of Honor.
"We are delighted and proud that Ed is joining the leadership of Constellation at this pivotal point as we grow our team and make important progress with our R&D programs," said Mark A. Goldsmith, M.D., Ph.D., Chief Executive Officer of Constellation Pharmaceuticals. "He has an outstanding record of achievement in science and he has collaborated with and advised both young and established pharmaceutical companies. Our company is built on a tradition of rigorous
science, and Ed`s proven ability to lead breakthrough research coupled with his deep relationships across academia and industry will help us to achieve high impact on behalf of patients."
"I am excited to join this impressive organization and believe the depth and quality of Constellation`s scientists and drug discovery platform position it to continue leading the field," said Dr. Harlow. "Epigenetics is an intriguing window into the complex biology of multiple diseases, and Constellation offers a compelling opportunity to leverage my experience in order to create innovative medicines."
Dr. Harlow has served on a number of influential advisory groups, including the Board of Life Sciences for the National Research Council, External Advisory Boards for UCSF, Stanford, UCLA, and NYU Cancer Center, and Scientific Advisory Boards for the Foundation for Advanced Cancer Studies and numerous biotechnology and pharmaceutical companies, including Onyx, Alnylam, 3V Biosciences, and Pfizer Pharmaceuticals. He received his B.S. and M.S. from the University of
Oklahoma and his Ph.D. at the Imperial Cancer Research Fund in London.
